Condition: Eosinophilic Esophagitis · Sponsor: Children's Hospital Medical Center, Cincinnati
This is a prospective, open-label drug study that will examine the effects of Zemaira (alpha-1 trypsin inhibitor) in patients with Eosinophilic Esophagitis.
This description comes directly from the study's public registry record.
Regina Yearout · (513) 517-2108 · Regina.Yearout@cchmc.org
Always discuss trial participation with your own doctor first.
| The National Institutes of Health | Bethesda, Maryland, United States | Recruiting |
| Cincinnati Children's Hospital Medical Center | Cincinnati, Ohio, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05485155